PTGS2 and lung carcinoma: Accordingly, COX-2 inhibitors combined with chemotherapy significantly inhibit the growth of human lung cancer cells.42,43 Celecoxib, a highly selective COX-2 inhibitor, can be used in combination with chemotherapy for patients with NSCLC after previous monotherapy failure.38 Our previous study.32 confirmed a PFS benefit after systematic treatment combined with celecoxib in patients with advanced NSCLC.